Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) Stock Short Interest Report for September

Posted by Francis Steltz on Oct 15th, 2026

Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report) saw a large growth in short interest in September. As of September 30th, there was short interest totaling 832,088 shares, a growth of 84.9% from the September 15th total of 449,962 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average trading volume of 519,457 shares, the short-interest ratio is presently 1.6 days.

Latigo Biotherapeutics Price Performance

Latigo Biotherapeutics stock opened at $14.00 on Thursday. Latigo Biotherapeutics has a 52 week low of $13.85 and a 52 week high of $25.93. The stock’s 50-day simple moving average is $20.06.

Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last announced its quarterly earnings results on Thursday, September 3rd. The company reported ($27.59) earnings per share for the quarter.

Insider Transactions at Latigo Biotherapeutics

In related news, Director James B. Tananbaum purchased 140,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the purchase, the director directly owned 2,008,024 shares in the company, valued at $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Foresite Capital Management V, purchased 140,000 shares of the stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $2,520,000.00. Following the transaction, the insider directly owned 2,008,024 shares in the company, valued at approximately $36,144,432. The trade was a 7.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LTGO. Guggenheim initiated coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price objective for the company. The Goldman Sachs Group started coverage on shares of Latigo Biotherapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $73.00 target price on the stock. Leerink Partners assumed coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $36.00 price target on the stock. Jefferies Financial Group initiated coverage on shares of Latigo Biotherapeutics in a research note on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price target for the company. Finally, Wall Street Zen raised shares of Latigo Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Four investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $52.25.

Check Out Our Latest Research Report on Latigo Biotherapeutics

About Latigo Biotherapeutics

(Get Free Report)

Latigo Biotherapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing non-opioid treatments for acute and chronic pain. The company’s research centers on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of creating therapies that may provide pain relief without the risks associated with opioid medicines.

Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, including LTG-001, an investigational candidate being evaluated for pain-related conditions.